Investor Presentaiton
Recap of progress on our key FY19 priorities and some
emerging challenges
India
• Strong Y-o-Y growth in India business (↑ 22%)
Cipla
St
US
South
Africa
EM
Quality
•
Differentiated approvals: Isoproterenol HCI Inj and
Testosterone Cypionate Inj
Filings: 5 ANDAs filed in Q1; on track to file 20+ in FY19
• 15% Cipla vs 7% market growth; first biosimilar launch
planned for Q2
•
Mirren* acquisition to give OTC boost
Biosimilar portfolio development efforts underway
Trastuzumab: deal signed for key Emerging Markets (ANZ,
Colombia and Malaysia)
EIR received for Goa & Indore plants
*Deal is subject to South Africa Competition Commission Approval
Investor Presentation: Q1FY19
08-08-2018
Emerging Challenges
China, commodities and oil linked cost
inflation pressure
Continued geo-political volatility in
emerging markets
11View entire presentation